Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Randomised, Double-blind, Placebo-controlled Study of HIV-1 Vaccines MVA.HTI and ChAdOx1.HTI With TLR7 Agonist Vesatolimod (GS-9620) in Early Treated HIV-1 Infection

NCT04364035 is registered in ClinicalTrials.gov with Aelix Therapeutics as lead sponsor.

NCT NCT04364035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04364035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Randomised, Double-blind, Placebo-controlled Study of HIV-1 Vaccines MVA.HTI and ChAdOx1.HTI With TLR7 Agonist Vesatolimod (GS-9620) in Early Treated HIV-1 Infection
Lead sponsor
Aelix Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
February 20, 2020
Completion date
December 16, 2022
Enrollment
50 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hiv/aids